Invivyd (NASDAQ:IVVD) CFO Sells $15,477.00 in Stock

Invivyd, Inc. (NASDAQ:IVVD) CFO William Duke sold 18,425 shares of Invivyd stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total value of $15,477.00. Following the sale, the chief financial officer owned 168,937 shares of the company’s stock, valued at approximately $141,907.08. This represents a 9.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Stock Performance

Shares of NASDAQ IVVD opened at $0.95 on Friday. The stock has a market cap of $280.26 million, a price-to-earnings ratio of -2.88 and a beta of 0.71. The business has a 50 day simple moving average of $0.78 and a 200 day simple moving average of $1.22. Invivyd, Inc. has a 52 week low of $0.48 and a 52 week high of $3.07.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The business had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. On average, analysts predict that Invivyd, Inc. will post -0.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of Invivyd in a report on Tuesday. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. BTIG Research reissued a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Invivyd has an average rating of “Hold” and a consensus target price of $8.00.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. OMERS ADMINISTRATION Corp raised its position in shares of Invivyd by 9.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 106,900 shares of the company’s stock valued at $139,000 after purchasing an additional 8,800 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Invivyd by 54.3% during the 1st quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company’s stock worth $35,000 after buying an additional 9,568 shares during the period. Courier Capital LLC bought a new stake in shares of Invivyd during the 4th quarter worth $25,000. Bronte Capital Management Pty Ltd. acquired a new position in Invivyd in the 4th quarter valued at $27,000. Finally, DRW Securities LLC acquired a new position in Invivyd in the 4th quarter valued at $27,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.